FDA (Image: AP)
FDA experts vote to yank the agency's 2011 OK of controversial preterm birth drug after a trial failure
Should AMAG continue to be allowed to sell their therapy for preventing preterm births even though their long-running confirmatory study flopped — badly?
That was …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
